Abpro Holdings, Inc.

Abpro Holdings, Inc. (Nasdaq: ACAB) is a clinical-stage biopharmaceutical company focused on the development of multi-specific antibody therapeutics targeting oncology and immunological diseases. The company entered the public markets through a SPAC transaction and operates within the life sciences and biotechnology sector. On August 23, 2024, Abpro filed a Form 10-Q with the SEC under accession number 0001193125-24-206165, reflecting its status as a reporting public company. Investors and analysts tracking de-SPAC issuers in the biopharma space can find detailed filing histories, deal timelines, and sponsor data for Abpro Holdings and thousands of comparable transactions by signing up for full access at SpacDesk.